Related Experiment Video
Updated: Jun 6, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
Chen Lü1, Andrew K Williams, Venu Chalasani
1Divisions of Urology and Surgical Oncology, Departments of Surgery and Oncology, University of Western Ontario, London, Ontario, Canada.
Importance Of The Field:
Prostate cancer is the leading malignancy in North American men and despite improvements in treatments 20 - 30% of patients will relapse. Immunotherapy using activated mononuclear cells is a way to harness the body's adaptive immune response to fight metastatic prostate cancer.
Areas Covered In This Review:
In 2005, at least 10 therapeutic cancer vaccines, designed to confer active, specific immunotherapy against tumor-associated antigens, were in clinical trials. These covered potential fields of immunological strategy to overcome castration-resistant prostate cancer.
What The Reader Will Gain:
A literature review was performed using the search terms sipuleucel-T, Provenge and APC8015 or APC-8015, and restricted to English language articles from 2000 to 2010. The immunological design and development of sipuleucel-T are summarized. The efficacy and safety of sipuleucel-T are discussed based on current data from clinical trials. Ongoing clinical trials involving sipuleucel-T are summarized.
Take Home Message:
Efficacy and safety with sipuleucel-T has been demonstrated in Phase I/II trials. The latest data from a Phase III trial shows that sipuleucel-T has met the primary endpoint of survival benefit. Further work is needed to understand the mechanisms behind cancer vaccine failure and elucidate the population for whom this vaccine will be suitable.
Insights
Sipuleucel-T (APC8015) immunotherapy demonstrates efficacy and safety in prostate cancer trials, offering a survival benefit. Further research is needed to optimize its use in specific patient populations.
Area of Science:
- Immunotherapy
- Prostate Cancer Treatment
- Cancer Vaccines
Background:
- Prostate cancer is a leading malignancy in North American men with a 20-30% relapse rate.
- Activated mononuclear cell immunotherapy harnesses the adaptive immune response against metastatic prostate cancer.
Purpose of the Study:
- To summarize the immunological design and development of sipuleucel-T (APC8015).
- To review the efficacy and safety data of sipuleucel-T from clinical trials.
- To summarize ongoing clinical trials involving sipuleucel-T.
Main Methods:
- Literature review of English articles from 2000-2010.
- Search terms included sipuleucel-T, Provenge, and APC8015.
- Analysis of data from Phase I, II, and III clinical trials.
Main Results:
- Sipuleucel-T demonstrated efficacy and safety in Phase I/II trials.
- Phase III trial data indicates sipuleucel-T meets the primary endpoint for survival benefit.
- The review summarizes the immunological design and clinical data for sipuleucel-T.
Conclusions:
- Sipuleucel-T has shown demonstrated efficacy and safety in early-phase trials.
- A significant survival benefit was observed in a Phase III trial.
- Further research is required to understand cancer vaccine failure mechanisms and identify optimal patient populations for sipuleucel-T.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...